SRS Capital Advisors Inc. Has $1.78 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

SRS Capital Advisors Inc. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 49.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,913 shares of the company's stock after buying an additional 3,611 shares during the period. SRS Capital Advisors Inc.'s holdings in Zoetis were worth $1,778,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. Callahan Advisors LLC grew its holdings in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. Pensionfund Sabic boosted its position in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. CIBC Asset Management Inc increased its stake in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. PFW Advisors LLC acquired a new stake in Zoetis during the 4th quarter worth about $1,764,000. Finally, Alberta Investment Management Corp lifted its stake in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock valued at $4,904,000 after buying an additional 28,700 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock traded down $2.94 during mid-day trading on Wednesday, reaching $166.96. The company had a trading volume of 3,666,720 shares, compared to its average volume of 3,280,356. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $74.76 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94. The company has a 50 day moving average of $166.53 and a 200-day moving average of $177.06. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis's payout ratio is 36.56%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZTS. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com downgraded Zoetis from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and an average price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.